An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells

Oncogene

Volumn 29, Issue 50, 2010, Pages 6522-6532

  Alameda, J P ^a   Moreno Maldonado, R ^a   Navarro, M ^a   Bravo, A ^b   Ramirez A ^a   Page, A ^a   Jorcano, J L ^a   Fernandez Aceero M J ^c   Casanova, M L ^a  

^a CIEMAT   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

angiogenesis; CYLD; skin cancer; tumor progression

Indexed keywords

ANGIOGENIC FACTOR; PROTEIN CYLD; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPIDERMAL SQUAMOUS CELL CARCINOMA; EPIDERMIS CELL; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650305124     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.378     Document Type: Article

References (59)

1. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
2. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. (2000). Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25: 160-165.
3. Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB, Conti CJ. (1998). Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 19: 2107-2113.
4. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797-801.
5. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. (1999). Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 18: 7423-7431.
6. Carmeliet P. (2003). Angiogenesis in health and disease. Nat Med 9: 653-660.
7. Casanova ML, Bravo A, Martinez-Palacio J, Fernandez-Acenero MJ, Villanueva C, Larcher F et al. (2004). Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice. Faseb J 18: 1556-1558.
8. Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C et al. (2002). A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62: 3402-3407.
9. Clevers H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
10. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS. (2000). Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131.
11. Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A et al. (2005). Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2: e199.
12. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. (2003). NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643.
13. De Francesco V, Frattasio A, Pillon B, Stinco G, Scott CA, Trotter D et al. (2005). Carcinosarcoma arising in a patient with multiple cylindromas. Am J Dermatopathol 27: 21-26.
14. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, Van Oers MH et al. (2004). Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101: 6122-6127.
15. Detmar M. (2000a). The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24(Suppl 1): S78-S84.
16. Detmar M. (2000b). Tumor angiogenesis. J Investig Dermatol Symp Proc 5: 20-23.
17. Durani BK, Kurzen H, Jaeckel A, Kuner N, Naeher H, Hartschuh W. (2001). Malignant transformation of multiple dermal cylindromas. Br J Dermatol 145: 653-656.
18. EVan G, Littlewood T. (1998). A matter of life and cell death. Science 281: 1317-1322.
19. Ferrara N. (2000). VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11: 617-624.
20. Ferrara N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803.
21. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676.
22. 0 Flanking and first intron sequences of the human beta-actin gene required for efficient promoter activity. Nucleic Acids Res 17: 253-270.
23. Green DR, EVan GI. (2002). A matter of life and death. Cancer Cell 1: 19-30.
24. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
25. Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A et al. (2004). Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 17: 617-622.
26. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. (2007). Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21-27.
27. Hirai Y, Kawamata Y, Takeshima N, Furuta R, Kitagawa T, Kawaguchi T et al. (2004). Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int J Oncol 24: 977-986.
28. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D et al. (2007). Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110: 3291-3300.
29. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. (2007). Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
30. Kinzler KW, Vogelstein B. (1996). Lessons from hereditary colorectal cancer. Cell 87: 159-170.
31. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. (2003). The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805.
32. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. (1998). VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17: 303-311.
33. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A et al. (1996). Up-regulation of vascular endothelial growth factor/ vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56: 5391-5396.
34. Li H, Zhu X, Zhang Y, Xiang J, Chen H. (2009). Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. J Exp Clin Cancer Res 28: 110.
35. Limmer BL. (2001). Nonmelanoma skin cancer: today's epidemic. Tex Med 97: 56-58.
36. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665-677.
37. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T et al. (2009). Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206: 221-232.
38. Massoumi R, Paus R. (2007). Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays 29: 1203-1214.
39. Mirones I, Conti CJ, Martinez J, Garcia M, Larcher F. (2009). Complexity of VEGF responses in skin carcinogenesis revealed through ex vivo assays based on a VEGF-A null mouse keratinocyte cell line. J Invest Dermatol 129: 730-741.
40. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. (2004). WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
41. Moreno-Maldonado R, Ramirez A, Navarro M, Fernandez-Acenero MJ, Villanueva C, Page A et al. (2008). IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas. Cell Cycle 7: 2021-2029.
42. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. (1991). Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 4: 196-202.
43. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS et al. (2005). Wnts induce migration and invasion of myeloma plasma cells. Blood 106: 1786-1793.
44. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R et al. (2003). The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med 198: 1959-1964.
45. Ren Q, Kari C, Quadros MR, Burd R, McCue P, Dicker AP et al. (2006). Malignant transformation of immortalized HaCaT kerati-nocytes through deregulated nuclear factor kappaB signaling. Cancer Res 66: 5209-5215.
46. Scharstuhl A, Mutsaers HA, Pennings SW, Russel FG, Wagener FA. (2009). Involvement of VDAC, Bax and ceramides in the efflux of AIF from mitochondria during curcumin-induced apoptosis. PLoS One 4: e6688.
47. Seitz CS, Lin Q, Deng H, Khavari PA. (1998). Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95: 2307-2312.
48. Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP. (1999). Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 93: 3824-3830.
49. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. (1995). Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 131: 796-800.
50. Strobel P, Zettl A, Ren Z, Starostik P, Riedmiller H, Storkel S et al. (2002). Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am J Surg Pathol 26: 119-124.
51. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD et al. (2007). Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104: 7516-7521.
52. Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-Van Dijk MR et al. (2010). Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 37: 607-619.
53. Thornburg NJ, Pathmanathan R, Raab-Traub N. (2003). Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 63: 8293-8301.
54. Thurston G, Murphy TJ, Baluk P, Lindsey JR, McDonald DM. (1998). Angiogenesis in mice with chronic airway inflammation: strain-dependent differences. Am J Pathol 153: 1099-1112.
55. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796.
56. Van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R. (1999). Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59: 3299-3303.
57. 0-flanking region of the gene. Differentiation 43: 105-114.
58. Zhang W, Wang Z, Chen T. (2010). Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells. Med Oncol 37: 607-619.
59. Zhong S, Fields CR, Su N, Pan YX, Robertson KD. (2007). Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621-2634.